Sanofi (XPAR:SAN) Future 3-5Y EPS without NRI Growth Rate : 17.06 (As of May. 18, 2025)

View and export this data going back to 1999. Start your Free Trial

What is Sanofi Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Sanofi's Future 3-5Y EPS without NRI Growth Rate is 17.06.

Competitive Comparison of Sanofi's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Sanofi's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sanofi's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Sanofi (XPAR:SAN) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Sanofi Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Sanofi's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (XPAR:SAN) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:USA SNY N:Mexico 1SAN:Italy 0A2V:UK SANp:UK 0O59:UK SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, Avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.